spacer
home > ict > autumn 2009 > liability insurance: protection in the clinical trial setting
PUBLICATIONS
International Clinical Trials

Liability Insurance: Protection in the Clinical Trial Setting

 

Product liability insurance, in its purest form, does not normally include the liability of an unproven, unregulated product in its testing stages. Usually, this is not a problem for manufacturers, since products are not distributed until the company and regulators feel the products are safe under normal use circumstances.

In the case of pharmaceuticals, medical devices or diagnostics, this is not the case. Testing is normally conducted in phases that can span years. Especially in the later phases of testing during clinical trials, there may be significant, uninsured liabilities incurred by the drug sponsor. These potential liabilities have created the need for clinical trials liability insurance. While sometimes referred to as ‘products liability’, their intent is to restrict coverage to the trial itself.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
5
     

There are no comments in regards to this article.

spacer
Harry Wallace is the Practice Leader for RCM&D’s Life Science and High Technology Group where he oversees the delivery of risk management products and services to these industries. He has over 30 years of experience in the insurance industry. Prior to becoming a broker, he was employed by the Chubb Group of Insurance Companies for 21 years where he held several senior level and management positions. Harry is a graduate of Texas A&M University. He holds a Certified Insurance Counselor designation and is a member of the Professional Liability Underwriting Society. Harry was recently recognised as one of six ‘Power Brokers’ for 2009 by Risk and Insurance magazine in the area of pharmaceuticals.
spacer
Harry Wallace
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Breakthrough in the global battle against polio: AJ Vaccines granted WHO prequalification for new polio vaccine

Despite ongoing concerted efforts to eradicate polio, it appears to be on the rise again with more cases registered in 2019 than 2018. Looking ahead, AJ Vaccines’ dose sparing technology provides a significant opportunity to expand supply, with the potential to deliver up to 100 million doses over the five-year period 2020-2024 to help meet the currently unmet global demand for inactivated polio vaccines.
More info >>

White Papers

Bio/Pharmaceutical Methods: Do your Analytical Methods Hold Up to Regulatory Scrutiny?

Eurofins BioPharma Product Testing

As FDA guidelines evolve and drug products on the market begin to age, bio/pharmaceutical manufacturers face scrutiny of the original methods used to support these products. Therefore, manufacturers must re-evaluate these methods to ensure they comply with current FDA expectations. Some manufacturers are even facing consent decrees imposed by the agency requiring them to bring methods up to current standards within a specified timeframe. This exercise requires significant amounts of time and resources, which many manufacturers do not have since they are focused on getting their next products to market. For that reason, some clients have been turning to Eurofins Lancaster Laboratories for support.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement